MedTrace Logo

Pilot Evaluation of CVT-E002 in Pediatric Upper Respiratory Tract Infection.

NCT00255307 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2007-06-18

No results posted yet for this study

Summary

This is a randomized double-blind three-arm trial to evaluate two dosages of CVT-E002 against placebo in pediatric upper respiratory tract infections (URTI). It is hypothesized that CVT-E002 use at standard doses reduces the duration of URTI in children aged 3-12 years.

Conditions

  • Upper Respiratory Infection

Interventions

DRUG

CVT-E002 ginseng extract

Sponsors & Collaborators

  • University of Alberta

    collaborator OTHER

  • Capital Health, Canada

    collaborator OTHER

  • CV Technologies

    lead INDUSTRY

Principal Investigators

  • Sunita Vohra, MD · University of Alberta/Capital Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
3 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-11-30
Completion
2006-04-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00255307 on ClinicalTrials.gov